Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HCFA Updated OPPS List Includes 456 Devices Eligible For Higher Payments

This article was originally published in The Gray Sheet

Executive Summary

The Health Care Financing Administration's most recent update to its list of devices eligible for reimbursement under the Medicare outpatient prospective payment system appears to address industry's concern that the system would establish an artificial market for certain devices.

You may also be interested in...



Medicare OPPS Administrative Burden On CMS Is Of Concern To MedPAC

The Medicare Payment Advisory Commission's upcoming recommendation on the future of the hospital outpatient prospective payment system (OPPS) "pass-through" payments is likely to hinge on the panel's perception of the size of the administrative undertaking for the Center for Medicare & Medicaid Services in implementing the system

Medicare OPPS Administrative Burden On CMS Is Of Concern To MedPAC

The Medicare Payment Advisory Commission's upcoming recommendation on the future of the hospital outpatient prospective payment system (OPPS) "pass-through" payments is likely to hinge on the panel's perception of the size of the administrative undertaking for the Center for Medicare & Medicaid Services in implementing the system

Medtronic IsoMed Implantable Drug Pump Approval Has Dual Indications

FDA's July 24 approval of Medtronic's IsoMed constant-flow implantable drug pump covers the dual indications of cancer therapy and pain management.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel